What We Do
At Sandoz our work is focused on improving access to medicines, access to medical information and access to medical capacity building.
Patients and Caregivers
We recognize the importance of patients and caregivers understanding what they can expect from us.
Search for openings and apply for positions at Sandoz locations worldwide.
Sandoz investing to increase production of much-needed antibiotics
Sandoz is pushing ahead with its capacity expansion program for much-needed antibiotic medicines. As shown in the photo, construction of a new USD 50m plant, announced in November 2022, is already well underway. Our Kundl site in Austria will also manufacture antibiotics for children (pediatric formulations). In total, the company is investing USD 250m to expand its antibiotic manufacturing capabilities in Europe. This has already led to a double-digit increase in capacity in 2022 and another double-digit increase is planned for 2023.
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Products & Services
At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine.
We are a pioneer and a global leader in biosimilars with over a decade of experience.